Gabapentin

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Neuroleptic-Induced Tremor

Conditions

Neuroleptic-Induced Tremor

Trial Timeline

Mar 1, 2004 → Aug 1, 2007

NCT ID

NCT00533455

About Gabapentin

Gabapentin is a phase 3 stage product being developed by Pfizer for Neuroleptic-Induced Tremor. The current trial status is terminated. This product is registered under clinical trial identifier NCT00533455. Target conditions include Neuroleptic-Induced Tremor.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01441401	Pre-clinical	Completed	Dec 1, 2011	Sep 1, 2014	Epilepsies, Partial
NCT00620555	Phase 3	Completed	May 1, 2008	Dec 1, 2010	Epilepsies, Partial
NCT00603473	Phase 3	Completed	Jan 1, 2008	Dec 1, 2009	Epilepsies, Partial
NCT00567268	Pre-clinical	Completed	Aug 1, 2007	May 1, 2014	Epilepsies, Partial
NCT00659100	Phase 3	Completed	Aug 1, 2006	Jan 1, 2007	Transient Insomnia
NCT00577967	Pre-clinical	UNKNOWN	Oct 1, 2005	Mar 1, 2006	Pruritus
NCT00533455	Phase 3	Terminated	Mar 1, 2004	Aug 1, 2007	Neuroleptic-Induced Tremor
NCT00137735	Phase 3	Completed	Oct 1, 2003	Dec 1, 2006	Carpal Tunnel Syndrome
NCT00644748	Approved	Completed	May 1, 2003	Aug 1, 2004	Diabetic Neuropathies
NCT00169013	Approved	Completed	May 1, 2002	Jun 1, 2006	Amputation of Lower Limb

Competing Products

1 competing product in Neuroleptic-Induced Tremor

See all competitors

Product	Company	Stage	Hype Score
Sarizotan	Merck	Pre-clinical	18